Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2020-03-17 Audit Report / Informat…
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing from a Korean company (EUGENE) titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (unqualified/proper), key financial data (assets, liabilities, equity, profit/loss), and auditor information. While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report to the exchange, rather than the full annual report (10-K) or a standalone audit report document (AR). Given the structure and the nature of the disclosure, it fits the 'Regulatory Filings' category as a fallback for this type of specific Korean market disclosure. FY 2019
2020-03-17 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by Eyegene Inc. It contains the meeting agenda, date, location, and detailed management information regarding the company's business, R&D, and financial status (Management Reports/Business Overview). This type of document is a standard Proxy Solicitation and Information Statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2020-03-12 Korean
투자판단관련주요경영사항(당뇨망막증치료제 ‘EG-Mirotin' 국내 임상 제2상 시험계획 승인)
Legal Proceedings Report Classification · 95% confidence The document is a regulatory disclosure from the company 'Eutilex' (아이진) regarding the approval of a Phase 2 clinical trial for its drug 'EG-Mirotin' by the Ministry of Food and Drug Safety (MFDS). This type of disclosure, which reports a significant business event or regulatory milestone, is classified as a general regulatory filing (RNS) in the absence of a more specific category like 'Legal Proceedings' or 'M&A'.
2020-03-12 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by the company '아이진'. It outlines the date, location, and agenda items (such as approval of financial statements and director compensation) for the upcoming meeting. This type of document is a standard proxy solicitation or notice of meeting material provided to shareholders to inform them of the meeting and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2020-03-10 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company (Eyegene) must hold its AGM on a date that coincides with other companies' meetings. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves, the proxy statement, or the results, it falls under the general regulatory filing category.
2020-03-10 Korean
기타경영사항(특허권취득)(자율공시)(면역반응 조절물질을 포함하는 백신 조성물 및 이의 용도)
Investor Presentation Classification · 95% confidence The document is a regulatory disclosure from a Korean company (Eutilex/Eyegene) regarding the acquisition of a patent ('특허권 취득'). It follows the standard format for 'Other Management Matters' (기타 경영사항) filings in the Korean stock market (DART system). Since this is a specific corporate announcement regarding a material business development (patent acquisition) that does not fit into financial reporting, dividend, or governance categories, it is classified as a general regulatory filing.
2020-03-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.